OncoMatch/Clinical Trials/NCT05800574
Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer
Is NCT05800574 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cisplatin for oropharynx cancer.
Treatment: Cisplatin — This is a prospective, phase II, stratified single arm investigation for favorable prognosis in p16+ oropharynx cancer patients with either node negative or malignant neck adenopathy with lymphoscintigraphy mapping confined to the ipsilateral neck.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A p16 overexpression (moderate to severe staining in at least 70% of cells) (moderate to severe staining in at least 70% of cells)
Immunohistochemical staining for p16 that demonstrates moderate to severe staining in at least 70% of cells.
Disease stage
Required: Stage CN3 (AJCC 8th edition)
Nodal status (based on staging manual, AJCC (American Joint Committee on Cancer) 8th ed.): N0 (provided the tumor is within 1cm of midline) N1> 1 lymph nodes (on the same side of the neck as the primary cancer) or cN3 (cranial nerve III) with no contralateral neck adenopathy; Tumor stage T1-2 that approaches within 1 cm but does not cross midline
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Prior systemic therapy for the study cancer
Cannot have received: head and neck cancer surgery that involved the neck (includes excisional biopsy)
Prior head and neck cancer surgery that involved the neck (includes excisional biopsy)
Cannot have received: radiation therapy to the head and neck
Exception: would result in overlap of treated fields
Prior radiation therapy to the head and neck that would result in overlap of treated fields
Cannot have received: gross total excision of the primary site in a diagnostic procedure
Exception: prior to either imaging and/or physical examination by registering physician
Gross total excision of the primary site in a diagnostic procedure prior to either imaging and/or physical examination by registering physician
Lab requirements
Blood counts
adequate hematologic function within 14 days prior to registration
Kidney function
adequate renal function within 14 days prior to registration
Liver function
adequate hepatic function within 14 days prior to registration
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify